Project Grant R01DA060066
Award Date 5/1/24
Completion Date 2/28/28
Dollars Obligated $3.5M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06519, USA
Similar Awards
- Federal Grant Award Summary The National Institute on Drug Abuse awarded a Project Grant of $182,697 (effective May 1, 2025, through August 30, 2026) to the University of Texas Health Science Center at San Antonio under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research evaluating cannabidiol (CBD) as an adjuvant therapeutic agent for opioid use disorder (OUD) treatment. The research addresses a critical public health challenge, as approximately half of OUD patients...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The University of Kentucky Research Foundation a $647,142 Project Grant on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct controlled research examining the impact of cannabis on opioid self-administration in individuals with opioid use disorder. The research will be completed by November 30, 2030, and will deliver fundamental public health data addressing a critical gap...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Albert Einstein College of Medicine a $199,584 Project Grant, effective March 15, 2026, through February 28, 2031, under the Drug Use and Addiction Research Programs (CFDA 93.279). Dr. Michele Buonora will conduct a five-year hybrid effectiveness-implementation study examining patient-controlled analgesia (PCA) for acute pain management in hospitalized individuals with opioid use disorder (POUD). The research will...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Massachusetts General Hospital $395,280 under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate AMP-C, a digital therapeutic (DTX) intervention targeting reward dysfunction in individuals with co-occurring Cannabis Use Disorder (CUD) and Major Depressive Disorder (MDD). This five-year project grant, effective July 1, 2025 through June 30, 2030, delivers a user-centered digital...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Regents of the University of Colorado-Denver a Project Grant totaling $2.89 million under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a comprehensive, multidisciplinary investigation of cannabis use's impact on pain and recovery following total knee arthroplasty (TKA) surgery. The research, which commenced September 5, 2025, and extends through August 31, 2030,...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Boston Children's Hospital a $489,500 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning June 1, 2025 and concluding May 31, 2027. This research initiative develops and validates remote oral fluid testing procedures to assess cannabis non-use as a key outcome measure in clinical trials targeting younger adults aged 18-30 years with cannabis use disorder (CUD). The project...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Washington University $1,320,580 under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on the analgesic potential of novel peripherally-restricted cannabinoid type 1 receptor (CB1R) ligands. The award, effective August 1, 2025, through April 30, 2030, funds preclinical research designed to bridge the gap between promising laboratory findings and inconsistent clinical...
- Federal Cooperative Agreement Summary The National Institute on Drug Abuse (NIDA) awarded a $1.37 million Cooperative Agreement to New York University School of Medicine, effective July 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test a telehealth-delivered transcranial direct current stimulation (tDCS) intervention for cannabis use disorder (CUD). The C.A.R.E.S. (Cannabis Addiction Recovery Enhancement Stimulation) Initiative combines home-based...
- Syncanica Bio, Inc. received a Project Grant of $334,343 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded June 15, 2025, with completion targeted for May 31, 2027. The company is developing fully synthetic analogs of 8,9-dihydrocannabidiol (H2CBD) as therapeutic agents to treat substance use disorder (SUD), a public health crisis with limited treatment options. This research builds on preliminary evidence indicating that...
- Federal Cooperative Agreement Summary George Washington University received a $2.1 million Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research evaluating oxytocin (OXT), an FDA-approved medication, as a novel therapeutic intervention for opioid-induced respiratory depression (OIRD). The research initiative, awarded July 1, 2025, with completion expected June 30, 2027, addresses the critical...